Background Because of the debate about whether second-generation antipsychotic drugs
are better than first-generation antipsychotic drugs, we did a meta-analysis of randomised …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …

Context Despite improvements in mental health services in recent decades, it is unclear
whether the risk of mortality in schizophrenia has changed over time. Objective To explore …

In light of the large number of studies published since the 2004 update of Schizophrenia
Patient Outcomes Research Team psychopharmacological treatment recommendations, we …

Antipsychotic‐induced extrapyramidal adverse effects are well recognized in the context of
first‐generation antipsychotic drugs. However, the introduction of second‐generation …

BackgroundProblems with the diagnosis and treatment of schizophrenia have led for a call
to change strategy and focus on individual psychotic experiences. In recent years, research …

Antipsychotic drugs (APDs) are best classified as typical or atypical. The distinction is based
solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia …

Abstract Background: Guidance in the United States and United Kingdom has included
cognitive behavior therapy for psychosis (CBTp) as a preferred therapy. But recent advances …

Adverse Effects of Antipsychotic Medications | AAFP Advertisement search close brand logo
JOHN MUENCH, MD, MPH, AND ANN M. HAMER, PharmD, BCPP Am Fam Physician. 2010;81(5):617-622 …